New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
January 8, 2014
07:07 EDTAUXLAuxilium's Xiaflex shows positive Phase 4 results
Auxilium announced interim data from its Phase 4 retreatment study evaluating Xiaflex in adult patients with Dupuytren's contracture and a recurrent contracture with a palpable cord. Xiaflexis a biologic approved in the U.S., EU, Canada and Australia for the treatment of adult DC patients with a palpable cord, and has been granted Orphan Drug Designation in the U.S. by the FDA. 87% of recurrent contractures of metacarpophalangeal joints were successfully retreated. Patients showed an average 83% improvement in fixed flexion. 85% of recurrent contractures of proximal interphalangeal were successfully retreated. Retreatment with CCH was well tolerated.
News For AUXL From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
January 27, 2015
09:35 EDTAUXLAuxilium shareholders approve merger with Endo
Subscribe for More Information
January 22, 2015
14:03 EDTAUXLAuxilium to host special shareholder meeting
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use